Selecta Biosciences appoints Kevin Tan as CFO effective Sept 20, 2021

Cartesian Therapeutics, Inc.

Kevin Tan named CFO; succeeds Ann K. Donohue who steps down as interim CFO but remains VP Finance.
New CFO will receive $410K base salary, 40% target bonus, $75K signing bonus.
Granted option to purchase 750K shares vesting over 4 years (25% at 12 months, remainder monthly).
Tan previously served as Treasurer at Sarepta Therapeutics from July 2020 to September 2021.
Severance includes 12 months salary, pro-rata bonus, and accelerated equity vesting upon qualifying termination.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kevin Tan

Chief Financial Officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2021-09-20
Filed: September 20, 2021, 7:59 PM ET

On September 20, 2021, Selecta Biosciences, Inc. (the “Company”) announced that the Board of Directors (the “Board”) of the Company has appointed Kevin Tan as the Company’s Chief Financial Officer, effective upon the commencement of Mr. Tan’s full-time employment with the Company on September 20, 2021

Role change

Ann K. Donohue

interim principal financial officer and principal accounting officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2021-09-20
Successor: Kevin Tan
Filed: September 20, 2021, 7:59 PM ET

Ann K. Donohue resigned from her duties as the Company’s interim principal financial officer and principal accounting officer, effective as of the Effective Date, and will continue to serve as the Company’s Vice President, Finance moving forward.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Tan was appointed as Chief Financial Officer at Cartesian Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 20, 2021, Selecta Biosciences, Inc. (the “Company”) announced that the Board of Directors (the “Board”) of the Company has appointed Kevin Tan as the Company’s Chief Financial Officer, effective upon the commencement of Mr. Tan’s full-time employment with the Company on September 20, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ann K. Donohue resigned as interim principal financial officer and principal accounting officer at Cartesian Therapeutics, Inc..

Action: resigned
Role: interim principal financial officer and principal accounting officer

Exact text from the filing

Ann K. Donohue resigned from her duties as the Company’s interim principal financial officer and principal accounting officer, effective as of the Effective Date, and will continue to serve as the Company’s Vice President, Finance moving forward.

View on SEC.gov

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-21-000113

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.